ERBB2 and breast cancer: S6K1 expression increased 1.5-fold after trastuzumab treatment in trastuzumab-resistant Δ16HER-2 BC cells, and this result was not replicated under treatment in trastuzumab-sensitive WT HER2 BC cells.